Khalil Zaman
A5050148338- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Immunotherapy and Immune Responses
- Bone health and treatments
- BRCA gene mutations in cancer
- Mesenchymal stem cell research
- Hepatitis B Virus Studies
- Nanoplatforms for cancer theranostics
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Cancer Risks and Factors
- Peptidase Inhibition and Analysis
- Fibroblast Growth Factor Research
- Angiogenesis and VEGF in Cancer
- Bone health and osteoporosis research
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Pharmacogenetics and Drug Metabolism
University Hospital of Lausanne
2015-2024
University of Lausanne
2010-2024
Breast Center
2012-2023
Swiss Cancer Center Léman
2023
Hôpital Orthopédique de la Suisse Romande
2007-2022
Brooklyn Hospital Center
2021
Swiss Group For Clinical Cancer Research
2006-2020
International Centre for Diarrhoeal Disease Research
2012-2020
Kantonsspital Winterthur
2013-2019
Kantonsspital St. Gallen
2010-2019
Abstract Developing strategies to inflame tumors is critical for increasing response immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine promotes T-cell infiltration and enables responsiveness combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive innate immunity depended on cytotoxic CD4+ CD8+ T cells. LDRT elicited predominantly cells with features exhausted effector cells, a subset expressing NKG2D exhibiting...
Abstract Expansion of antigen-experienced CD8 + T cells is critical for the success tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer 1 . Interleukin-2 (IL-2) acts as a key regulator cytotoxic functions by promoting expansion and capability 2,3 Therefore, it essential to comprehend mechanistic barriers IL-2 sensing tumour microenvironment implement strategies reinvigorate responsiveness antitumour responses. Here we report that prostaglandin E2 (PGE 2...
Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is definitive. From September 2012-March 2013, 212 evaluable ER+ early BC, <37 years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey fertility concerns, desire interest study of endocrine therapy (ET) interruption...
Abstract Complementary medicine (CM) is used by one third to half of cancer patients throughout the world. The objective this study was describe prevalence CM use and potential for interactions with treatments in an academic oncology centre. A cross-sectional conducted among undergoing current treatment. Among 132 included patients, 56% had since their diagnosis 45% were using during treatment at time survey. main green tea (35%), herbal homeopathy (27%), dietary supplements medicines (27%)....
Purpose Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis. We analyzed long-term follow-up (LTFU) of efficacy outcomes and adverse events in the Breast International Group (BIG) 1-98 study reported median 12.6 years. Patients Methods BIG is four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) their sequences (2 one plus 3 other) postmenopausal women...
Estrogen and progesterone receptor (ER, PR) signaling control breast development impinge on carcinogenesis. ER is an established driver of + disease but the role PR, itself target gene, debated. We assess issue in clinically relevant settings by a genetic approach inject cancer cell lines patient-derived tumor cells to milk ducts immunocompromised mice. Such xenografts were exposed physiologically levels 17-β-estradiol (E2) (P4). find that independently both premenopausal E2 P4 increase...
Abstract Background Tucatinib is a highly selective HER2-directed tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for previously treated HER2+ locally advanced or metastatic breast cancer (LA/MBC). Trastuzumab emtansine (T-DM1) antibody-drug conjugate to treat LA/MBC taxane. This the first report of HER2CLIMB-02 (NCT03975647), randomized, double-blind, placebo-controlled phase 3 study assessing efficacy safety tucatinib combined T-DM1 patients LA/MBC....
506 Background: The 70-gene signature MammaPrint has been shown to identify breast cancer patients for whom adjuvant chemotherapy (CT) could be safely omitted even in the presence of unfavorable standard clinical-pathological criteria. MINDACT primary endpoint at 5 years median follow-up was met 2016 (Cardoso et al, NEJM 2016) with a distant metastasis free survival (DMFS) rate 94.7% (95% CI: 92.5-96.2) clinical high (C-High) / genomic low (G-Low) risk who received no CT. Longer is now...
Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis poor and more than three quarters of patients experience progression 12 months after the initiation conventional first-line chemotherapy. Approximately two thirds TNBC express epidermal growth factor receptor 1 (EGFR). We have developed anti-EGFR targeted nanocontainer drug by inserting antibody fragments into membrane pegylated liposomes (anti-EGFR-ILs-dox). payload consists...
1004 Background: Neratinib (HKI-272) is an orally administered irreversible pan-ErbB receptor tyrosine kinase inhibitor. In ongoing phase II study, the preliminary objective response rate was 26% in patients with ErbB2+ advanced breast cancer prior trastuzumab therapy. This study assessed safety and efficacy of combination neratinib plus trastuzumab. Methods: Patients that progressed following therapy were enrolled. The primary endpoint 16-week progression free survival (PFS). part 1 (dose...
The rates of influenza illness and associated complications are high among children in Bangladesh. We assessed the clinical efficacy safety a Russian-backbone live attenuated vaccine (LAIV) at two field sites Bangladesh.Between Feb 27 April 9, 2013, aged 2-4 years urban Kamalapur rural Matlab, Bangladesh, were randomly assigned 2:1 ratio, according to computer-generated schedule, receive one intranasal dose LAIV or placebo. After vaccination, we monitored weekly home visits until Dec 31,...
Introduction Up to one-fifth of breast cancer survivors will develop chronic cancer-related lymphoedema (BCRL). To date, complex physical decongestion therapy (CDT) is the gold standard treatment. However, it mainly symptomatic and often ineffective in preventing BCRL progression. Lymphovenous anastomosis (LVA) vascularised lymph node transfer (VLNT) are microsurgical techniques that aim restore lymphatic drainage. This international randomised trial aims evaluate advantages interventions...